Abstracts tagged "fibromyalgia"

Abstract Number: 2849 • 2013 ACR/ARHP Annual Meeting
Medication Adherence and Healthcare Costs Among Patients With Fibromyalgia: Combination Medication Versus Duloxetine, Pregabalin, and Milnacipran Initiators
Nicole Marlow¹, Kit Simpson², James Zoller² and E. Baron Short³, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Healthcare Leadership and Management, Medical University of South Carolina, Charleston, SC, ³Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
Background/Purpose: The combined use of prescription drugs (Rx) with complementary mechanisms of action has been described for treating fibromyalgia (FM). We examined medication adherence and…
Abstract Number: 2850 • 2013 ACR/ARHP Annual Meeting
Once Daily Controlled-Release Pregabalin In Fibromyalgia Patients: A Phase 3 Double-Blind, Randomized Withdrawal, Placebo-Controlled Study
Lesley M. Arnold¹, Pierre Arsenault², Cynthia Huffman³, Jeffrey L. Patrick⁴, Michael Messig⁴, Marci L. Chew⁴, Luis Sanin⁴, Lynne Pauer⁴ and Andrew Clair⁴, ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Département de Médecine de Famille, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Meridien Research, Tampa, FL, ⁴Pfizer Inc, New York, NY
Background/Purpose: Pregabalin (PGB) is currently approved for the treatment of fibromyalgia (FM) for twice daily dosing over a range of 300-450 mg/day. A pregabalin controlled-release…
Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting
Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia
John S. Sampalis^1,2, Mary-Ann Fitzcharles³, Peter A. Ste-Marie⁴, Emmanouil Rampakakis^1,2 and Yoram Shir⁴, ¹JSS Medical Research, Montreal, QC, Canada, ²Jewish General Hospital, McGill University, Montreal, QC, Canada, ³Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…
Abstract Number: 2092 • 2013 ACR/ARHP Annual Meeting
Strengthening Exercises Using A Swiss Ball Improve Symptoms and Muscle Performance Of Patients With Fibromyalgia: A Randomized Controlled Study
Josiander Arakaki Sr., RHEUMATOLOGY, UNIFESP, sao paulo, Brazil
Background/Purpose: Fibromyalgia (FM) is a disorder characterized by chronic widespread pain, fatigue and reduced muscle strength. Exercise is fundamental to the treatment of FM and…
Abstract Number: 1948 • 2013 ACR/ARHP Annual Meeting
Power Doppler Ultrasound 7-Joint Score Vs. Simplified Disease Activity Index In Rheumatoid Arthritis Associated With Fibromyalgia
Rafael Chakr¹, Marina Behar², José A. Mendonça³, Daniela Cervantes², Nizele Calegaro², Nicole Andrade², Iuri Siqueira², Daniel Zanchet², Andrese Gasparin², Penélope Esther Palominos², Charles Kohem⁴, Odirlei Andre Monticielo⁵, Claiton Brenol⁶, Ricardo M. Xavier² and João Carlos T. Brenol⁷, ¹Rheumatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Rheumatology, Pontifical Catholic University of Campinas / Institute of Clinical Research – IPECC, Campinas, Brazil, ⁴Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, ⁵Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁷Rheumatology Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: Fibromyalgia (FM) falsely increases rheumatoid arthritis (RA) disease activity clinical composite scores, such as the simplified disease activity index (SDAI), recently incorporated into ACR/EULAR…
Abstract Number: 140 • 2013 ACR/ARHP Annual Meeting
Fibromyalgia and Pregnancy: Challenges Of The Savella^® (Milnacipran) Pregnancy Registry
Damien Hirsch¹, Denise Leclair¹, Robert H. Palmer¹, Vikki Brown², Susan Sinclair Roberts^2,3 and Janice McLean², ¹Forest Research Institute, Inc., Jersey City, NJ, ²INC Research, LLC, Wilmington, NC, ³University of North Carolina Wilmington, Wilmington, NC
Background/Purpose: During pregnancy, women with fibromyalgia (FM) often experience worsening of symptoms, which include widespread pain, fatigue, sleep disturbances, cognitive difficulties, and reduced daily functioning.…
Abstract Number: 1101 • 2013 ACR/ARHP Annual Meeting
Neuromuscular Taping On Patients With Fibromyalgia May Be a Useful Tool To Relief Muscular Pain
Camillo Giacomelli, Antonino Santagati, Arianna Consensi, Alessandra Rossi, Stefano Bombardieri and Laura Bazzichi, University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Fibromyalgia (FMS) is an illness characterized by an anomalous perception of the painful stimuli that are supposed to be attributable to a combination of…
Abstract Number: 142 • 2013 ACR/ARHP Annual Meeting
Home Tender Point Measurement In Fibromyalgia Patients
Robert S. Katz¹, Hannah Bond² and Jessica L. Polyak², ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: To determine whether: 1) patients with the fibromyalgia syndrome (FMS) can accurately evaluate their own tender points, similar to self-administered testing for other purposes…
Abstract Number: 1094 • 2013 ACR/ARHP Annual Meeting
Hyperbaric Oxygen Ameliorates Fibromyalgia Symptoms and Functional Impairment – A Randomized Prospective Trial
Shai Efrati¹, Jacob N. Ablin², Yair Bechor³, Shir Daphna-Tekoah⁴, Gregory Fishlev⁵, Yifat Faran⁴, Jacob Bergan⁶, Mony Friedman⁶ and Dan Buskila⁷, ¹Research & Development Unit and Hyperbaric institute, Asaf-Harofeh medical center, Beer Yaacov, Zerifin, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Institute of Hyperbaric Medicine, Asaf-Harofeh medical center, Beer Yaacov, Zerifin, Israel, ⁴School of Social Work, Ashkelon Academic College, Ashkelon, Israel, ⁵Institute of Hyperbaric Medicine, Assaf Harofeh Medical Center, Beer Yaacov, Zerifin, Israel, ⁶Hyperbaric institute, Asaf-Harofeh medical center, Beer Yaacov, Zerifin, Israel, ⁷Ben-Gurion University, Beer-Sheva, Israel
Background/Purpose: Fibromyalgia Syndrome (FMS), considered to represent a prototype of central nervous system sensitization, is a common condition characterized by chronic widespread pain and diffuse…
Abstract Number: 143 • 2013 ACR/ARHP Annual Meeting
Rapid Infrared Microscopy (IRMS) For Differential Diagnosis Of Fibromyalgia and Other Central Sensitivity Syndromes
Kevin V. Hackshaw¹, Luis Rodriguez-Saona², Irving L. Rosenberg³, Marcal Plans² and C.A. Tony Buffington⁴, ¹Immunology/Rheumatology, The Ohio State University, Columbus, OH, ²Food Sciences, The Ohio State University, Columbus, OH, ³Immunology/ Rheumatology, The Ohio State University, Columbus, OH, ⁴Veterinary Biological Sciences, The Ohio State University, Columbus, OH
Background/Purpose: Background/Purpose: The aim of this study was to investigate the ability of a rapid blood-spot-based method for diagnosis of Fibromyalgia (FM) using mid-infrared microspectroscopy (IRMS)…
Abstract Number: 1097 • 2013 ACR/ARHP Annual Meeting
A Potential Use Of Neurotropin^TM, a Novel Neuro-Modulating Medication, For The Treatment Of Chronic Pain and Fibromyalgia
Kenji Miki^1,2,3, Ryota Hashimoto^4,5,6, Kenrin Shi^2,7,8 and Masao Yukioka⁸, ¹Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ²Center for Pain Management, Osaka University Hospital, Suita, Japan, ³Dept. of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁴Dept of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁵Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan, ⁶Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Suita, Japan, ⁷Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ⁸Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan
Background/Purpose: To date, no established treatment for chronic pain including fibromyalgia has been specified in Japan. Neurotropin, a non-protein extract isolated from the inflamed cutaneous…
Abstract Number: 120 • 2013 ACR/ARHP Annual Meeting
The Symptom Severity In Korean Patients With Fibromyalgia Is Associated With Socioeconomic Status, But Not With Obesity
Dong-Jin Park¹, Shin-Seok Lee², Seong-Ho Kim³, Seong-Su Nah⁴, Ji Hyun Lee⁵, Seong-Kyu Kim⁶, Yeon-Ah Lee⁷, Seung-Jae Hong⁷, Hyun-Sook Kim⁸, Hye-Soon Lee⁹, Hyoun Ah Kim¹⁰, Chung-Il Joung¹¹ and Sang-Hyon Kim¹², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ³Internal Medicine, Division of Rheumatology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Maryknoll Medical Center, Busan, South Korea, ⁶Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University of Korea, Seoul, South Korea, ⁹Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁰Ajou University Hospital, Suwon, South Korea, ¹¹Department of Internal Medicine, Konyang university hospital, Daejeon, South Korea, ¹²Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Fibromyalgia (FM) is a chronic pain disorder characterized by widespread pain, tenderness, and various associated symptoms including sleep disturbances, chronic fatigue, depression, and other…
Abstract Number: 1106 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Interdisciplinary Program For Fibromyalgia
Dianne Whiting¹, Debbi Huskey¹, Emily Rosario¹ and Samy Metyas^1,2, ¹Casa Colina Centers for Rehabilitation, Pomona, CA, ²University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, Covina, CA
Background/Purpose: Fibromyalgia (FM) affects 5 million Americans, and the prevalence is estimated to be 2- 6 percent in the general population. The symptoms associated with…
Abstract Number: 121 • 2013 ACR/ARHP Annual Meeting
Comparative Burden Of Chronic Widespread Pain and Fibromyalgia In The US Population
Caroline Schaefer¹, Rachael Mann², Elizabeth T. Masters³, Joseph C. Cappelleri⁴, Shoshana Daniel⁵, Gergana Zlateva³, Heather McElroy⁶, Arthi B. Chandran³, Edgar H. Adams¹, Annlouise R. Assaf⁴, Michael McNett⁷, Philip Mease⁸, Stuart L. Silverman⁹ and Roland Staud¹⁰, ¹Covance Market Access Services Inc., Gaithersburg, MD, ²Covance Market Access Services Inc., San Diego, CA, ³Pfizer Inc., New York, NY, ⁴Pfizer Inc., Groton, CT, ⁵Covance Market Access Services Inc., Conshohocken, PA, ⁶Covance Market Access Services, Sydney, Australia, ⁷Aurora Pain Program, Milwaukee, WI, ⁸Director, Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁹Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA, ¹⁰Dept Med/Rheum/Clin Immun Div, University of Florida, Gainesville, FL
Background/Purpose: Few data exist on the comparative burden of chronic widespread pain (CWP) and fibromyalgia (FM) in the general population. Methods: 8,382 nationally representative participants…
Abstract Number: 1108 • 2013 ACR/ARHP Annual Meeting
Methylphenidate Improves Concentration, Energy and Mood In Fibromyalgia
Robert S. Katz¹, Hannah Bond² and Frank Leavitt³, ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Central nervous system stimulants such as methylphenidate appear to have short term benefits for naming speed and cognitive functioning in fibromyalgia (FMS). Methylphenidate quickly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].